Anaplastic thyroid cancer (ATC) is among the most aggressive cancers with a median overall survival of 4 months and a disease-specific mortality of close to 100%. As soon as the diagnosis is suspected or established, urgent referral to an experienced multidisciplinary center is imperative. Chemotherapy has limited efficacy. Molecular analyses, together with the availability of novel targeted therapies and immunotherapies, now permit to improve outcomes. In particular, targeted therapy with dabrafenib and trametinib is indicated as first-line therapy for BRAF V600E-mutated ATC.
Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques [Anaplastic thyroid carcinoma : new therapeutic approaches]
La Rosa S;
2021-01-01
Abstract
Anaplastic thyroid cancer (ATC) is among the most aggressive cancers with a median overall survival of 4 months and a disease-specific mortality of close to 100%. As soon as the diagnosis is suspected or established, urgent referral to an experienced multidisciplinary center is imperative. Chemotherapy has limited efficacy. Molecular analyses, together with the availability of novel targeted therapies and immunotherapies, now permit to improve outcomes. In particular, targeted therapy with dabrafenib and trametinib is indicated as first-line therapy for BRAF V600E-mutated ATC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Revue Médicale Swiss 2021_ATC.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
DRM non definito
Dimensione
421.15 kB
Formato
Adobe PDF
|
421.15 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
